Janux Therapeutics (JANX) Net Income towards Common Stockholders (2020 - 2026)
Janux Therapeutics (JANX) reported Net Income towards Common Stockholders of -$24.4 million for Q1 2026, down 3.63% year-over-year from -$25.3 million in Q1 2025, and up 23.74% quarter-over-quarter from -$31.9 million in Q4 2025.
Janux Therapeutics (JANX) Net Income towards Common Stockholders (2020 - 2026) Analysis & Trends
Janux Therapeutics (JANX) has 7 years of Net Income towards Common Stockholders data on file, last reported at -$24.4 million in Q1 2026.
- Net Income towards Common Stockholders for Q1 2026 came in at -$24.4 million, down 3.63% year-over-year; the trailing twelve-month figure through Mar 2026 was -$114.5 million (down 47.25% YoY), and the FY2025 annual result was -$113.6 million, down 64.69% from the prior year.
- Net Income towards Common Stockholders advanced to -$24.4 million in Q1 2026 per JANX's latest filing, from -$31.9 million in the prior quarter.
- Over five years, Net Income towards Common Stockholders peaked at -$6.0 million in Q2 2024 and troughed at -$33.9 million in Q2 2025.
- A 5-year average of -$19.3 million and a median of -$17.5 million in 2023 frame the typical range for Net Income towards Common Stockholders.
- The sharpest annual moves came in 2022 and 2024: Net Income towards Common Stockholders plunged 487.13% in 2022, then soared 65.96% in 2024.
- A 5-year view of Net Income towards Common Stockholders shows it stood at -$16.1 million in 2022, then gained by 26.81% to -$11.8 million in 2023, then tumbled by 71.93% to -$20.2 million in 2024, then tumbled by 58.02% to -$31.9 million in 2025, then gained by 23.74% to -$24.4 million in 2026.
- Business Quant data shows JANX's Net Income towards Common Stockholders at -$24.4 million in Q1 2026, -$31.9 million in Q4 2025, and -$24.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -13.56 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 2.50 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.63 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Janux Therapeutics | 892.99 Mn | 892.99 Mn | - | -24.36 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -24.36 Mn |
| Dec 31, 2025 | -31.95 Mn |
| Sep 30, 2025 | -24.31 Mn |
| Jun 30, 2025 | -33.86 Mn |
| Mar 31, 2025 | -23.51 Mn |
| Dec 31, 2024 | -20.22 Mn |
| Sep 30, 2024 | -28.06 Mn |
| Jun 30, 2024 | -5.96 Mn |
| Mar 31, 2024 | -14.76 Mn |
| Dec 31, 2023 | -11.76 Mn |
| Sep 30, 2023 | -11.57 Mn |
| Jun 30, 2023 | -17.51 Mn |
| Mar 31, 2023 | -17.46 Mn |
| Dec 31, 2022 | -16.07 Mn |
| Sep 30, 2022 | -16.70 Mn |
| Jun 30, 2022 | -16.89 Mn |
| Mar 31, 2022 | -13.41 Mn |
| Dec 31, 2021 | -13.42 Mn |
| Sep 30, 2021 | -10.77 Mn |
| Jun 30, 2021 | -6.21 Mn |